The Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new Community of Practice for Digital Mental Health Technologies, a forum intended to strengthen regulatory understanding, shared learning and practical support for developers working in one of the fastest-growing segments of UK medtech.
The MHRA describes the move as a coordinated effort to help innovators navigate regulatory expectations, improve compliance and bring safe, effective digital mental health solutions into clinical use sooner. It responds to rising demand for clarity on evidence requirements, post-market responsibilities and the rules that apply to software-based and AI-enabled mental health tools.
A forum spanning developers, clinicians and regulators
The community will bring together developers, clinicians, researchers, commissioners and regulatory specialists to build a shared understanding of best practice. As the field expands, from therapeutic apps to AI-supported assessment tools, the announcement argues that consistent and practical guidance has become more urgent.
Stated objectives
- Helping developers interpret regulatory requirements and build compliance into product design at an earlier stage.
- Identifying the challenges innovators commonly face, particularly small and medium-sized enterprises entering the mental health space.
- Sharing real-world experience from organisations that are already working through regulatory pathways.
- Strengthening dialogue between industry and regulators so that emerging technologies continue to meet safety, performance and evidence expectations.
Survey to shape initial priorities
To decide where the community should start, the MHRA has opened a survey for digital mental health technology developers and other stakeholders across the medtech ecosystem. It asks about current regulatory difficulties, the areas where clearer guidance is needed and the opportunities to improve compliance support.
The regulator is seeking broad participation so that the community reflects real-world needs rather than top-down assumptions. Developers are encouraged to complete the survey and to circulate it within their organisations, with the agency presenting a strong response as a way to help the community deliver meaningful, practical support.
What it means for developers
For the wider medtech development community, the announcement frames the forum as an opportunity to engage the regulator directly on questions that often determine whether a promising technology reaches patients. The emphasis on early compliance and on smaller companies suggests attention to firms that may not have dedicated regulatory staff.
For developers, the practical value lies in shaping the support they will receive: the survey is positioned as a channel for influencing future guidance and for contributing to a more predictable, transparent environment for innovation.
The announcement did not set out a timetable, a membership process or a list of deliverables; the survey is presented as the first step in deciding what the community takes on.